Morgan Stanley
ASBP

Morgan Stanley’s Aspire Biopharma ASBP Stock Holding History

Morgan Stanley’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79.3K Buy
+2,565
New +$137K ﹤0.01% 6251

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.55B AUM 28.47% 1-Year Est. Return

Morgan Stanley's ASBP Position: Q1 2026 in Review

Morgan Stanley opened a new position in Aspire Biopharma (ASBP) in Q1 2026: 2,565 shares worth $79.3K. The stake represents ﹤0.01% of the portfolio and ranks #6251 among its holdings.

12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

  • Morgan Stanley held 2,565 shares of Aspire Biopharma worth $79.3K as of Q1 2026.
  • Aspire Biopharma was a new Morgan Stanley position in Q1 2026.
  • Aspire Biopharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6251 holding.
  • 12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.